{"id":"low-bile-acid-binding-blenderized-diet","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal symptoms (diarrhea, steatorrhea)"},{"rate":null,"effect":"Nutritional deficiencies (fat-soluble vitamins)"},{"rate":null,"effect":"Palatability/compliance issues"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This dietary intervention is designed to reduce the binding of bile acids in the intestinal lumen, thereby decreasing their reabsorption and increasing fecal excretion. By limiting bile acid reabsorption, the diet may help normalize bile acid metabolism and reduce associated metabolic complications. This approach is particularly relevant for patients with certain cholestatic or metabolic disorders where bile acid accumulation contributes to disease pathology.","oneSentence":"A specialized blenderized diet formulation that minimizes bile acid binding to reduce enterohepatic circulation and modify lipid metabolism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:53:16.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Progressive familial intrahepatic cholestasis (PFIC) and related cholestatic liver diseases"}]},"trialDetails":[{"nctId":"NCT06913621","phase":"","title":"The Use of High Bile-Binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 3)","status":"NOT_YET_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-07","conditions":"Feeding Difficulties, Gastrostomy, Aspiration","enrollment":138},{"nctId":"NCT07303868","phase":"PHASE4","title":"The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 2)","status":"NOT_YET_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-07","conditions":"Feeding Difficulties, Gastrostomy, Aspiration","enrollment":66},{"nctId":"NCT07303738","phase":"PHASE4","title":"The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 1)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2025-12-01","conditions":"Feeding Difficulties, Aspiration, Gastrostomy","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"low bile acid binding blenderized diet","genericName":"low bile acid binding blenderized diet","companyName":"Boston Children's Hospital","companyId":"boston-children-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A specialized blenderized diet formulation that minimizes bile acid binding to reduce enterohepatic circulation and modify lipid metabolism. Used for Progressive familial intrahepatic cholestasis (PFIC) and related cholestatic liver diseases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}